Paul J. Hergenrother wins the George & Christine Sosnovsky Award for Cancer Research.
- Timothy Fan and Paul Hergenrother have created PAC-1, a new drug to combat brain cancer.
- With help from an endowed chairship, Paul Hergenrother is improving antibiotics.
- Paul Hergenrother has won the Sosnovsky Award for Cancer Research, one of the National Awards of the American Chemical Society.
- Paul Hergenrother's team reports that they now know how to build a molecular Trojan horse that can penetrate gram-negative bacteria, solving a problem that for decades has stalled the development of effective new antibiotics against these increasingly drug-resistant microbes.
- Paul Hergenrother is this year's recipient of the Innovation Transfer Award - University of Illinois.
- Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline.
- Paul Hergenrother is the recipient of this year's UCB-Ehrlich Award for Excellence in Medicinal Chemistry.
- A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans.
- Paul Hergenrother, the Rinehart Professor of Chemistry, appears on the list of UIUC University Scholars named this year.
- Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials.
- Professor Hergenrother, Karen Morrison (graduate student), and coworkers at MIT have synthesized and tested several dozen compounds that may hold promise as potential cancer drugs.
- Professor Hergenrother and coworkers report that tweaking natural products' rings and functional groups could lead to better compound libraries for drug discovery.
- Vanquish Oncology, Inc. is a drug development company focused on targeting molecular defects in specific cancer cells to create personalized oncology therapeutics for unmet or underserved cancer markets.
- Researchers at the University of Illinois have designed a small molecule that blocks an aberrant pathway associated with myotonic dystrophy type 1, the most common form of muscular dystrophy.